Nucleotide competing reverse transcriptase inhibitors: Discovery of a series of non-basic benzofurano[3,2-d]pyrimidin-2-one derived inhibitors was written by James, Clint A.;DeRoy, Patrick;Duplessis, Martin;Edwards, Paul J.;Halmos, Teddy;Minville, Joannie;Morency, Louis;Morin, Sebastien;Simoneau, Bruno;Tremblay, Martin;Bethell, Richard;Cordingley, Michael;Duan, Jianmin;Lamorte, Louie;Pelletier, Alex;Rajotte, Daniel;Salois, Patrick;Tremblay, Sonia;Sturino, Claudio F.. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2013.Recommanded Product: 4457-67-4 This article mentions the following:
A HTS screen led to the identification of a benzofurano[3,2-d]pyrimidin-2-one core structure which upon further optimization resulted in I as a potent HIV-1 nucleotide competing reverse transcriptase inhibitor. Investigation of the SAR at N-1 allowed significant improvements in potency and when combined with the incorporation of heterocycles at C-8 resulted in potent analogs not requiring a basic amine to achieve antiviral activity. Addnl. modifications at N-1 resulted in II which demonstrated excellent antiviral potency and improved physicochem. properties. In the experiment, the researchers used many compounds, for example, 1-Bromo-4-methoxybutane (cas: 4457-67-4Recommanded Product: 4457-67-4).
1-Bromo-4-methoxybutane (cas: 4457-67-4) belongs to organobromine compounds. Bromine is more electronegative than carbon (2.9 vs 2.5). Consequently, the carbon in a carbon–bromine bond is electrophilic, i.e. alkyl bromides are alkylating agents. In the pharmaceutical industry organo bromine derivatives are used as sedatives, vasodilators, antiseptic agents, and anticancer agents.Recommanded Product: 4457-67-4
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary